Jiangsu Vcare Completes First Patient Enrollment in Phase II Clinical Trial of VC005 Topical Gel for Mild-to-Moderate Atopic Dermatitis
Published Time:
2025-04-28 18:00
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
In the Phase I clinical study completed in July, 2024, VC005 gel demonstrated excellent safety and significant efficacy. Compared to similar topical drugs already on the market, VC005 exhibits much lower systemic exposure in humans, potentially offering superior long-term safety for patients.
Additionally, the Phase III clinical trial for VC005 tablets, an oral formulation targeting moderate-to-severe AD, is currently enrolling participants. Preliminary results show significant patient benefits and a favorable safety profile.
About VC005
VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug is designed for the treating inflammatory and autoimmune diseases such as atopic dermatitis, ankylosing spondylitis, and rheumatoid arthritis. Compared to Upadacitinib, a leading marketed drug in its class, VC005 exhibits lower JAK2 inhibitory activity (based on in vitro kinase assay results), which may mitigate safety concerns associated with excessive JAK2 inhibition. Furthermore, since JAK1 synergizes with TYK2 in multiple diseases, VC005's high selectivity for JAK1 over JAK2 may translate into superior clinical efficacy relative to other drugs in its class.
About Atopic Dermatitis (AD)
Atopic dermatitis is a chronic, relapsing, inflammatory skin disease characterized by dry skin, intense itching, and eczematous rashes, significantly impairing patients' quality of life. Epidemiologically, the global AD patient population is approximately 230 million, with an adult prevalence rate of 2%–8% in China, affecting over 70 million individuals. Among these, 67% are mild cases, and 33% are moderate-to-severe. Frost & Sullivan predicts that cases will grow at a compound annual rate of 1.7% from 2025 to 2030. Traditional treatments, such as corticosteroids, are associated with numerous adverse reactions and limited long-term benefits, making it challenging to achieve effective and stable control. In contrast, topical JAK1 small-molecule targeted inhibitors, as non-steroidal immunomodulators, may enhance treatment safety for mild-to-moderate AD patients while maintaining therapeutic efficacy.
Related News
12
2026
/
11
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has officially launched a clinical trial for the new indication of bone metastatic cancer pain of Eratrectinib Capsules (VELMARTO®, VC004), a Class 1 innovative drug independently developed by the company. This move further expands the clinical application scope of this next-generation TRK inhibitor and explores an innovative treatment option for patients suffering from bone metastatic cancer pain.
28
2026
/
10
Recently, VC005 topical gel,balanced, highly selective new-generation JAK1 inhibitor, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially received the IND clearance from the NMPA. It is intended for the topical treatment of seborrheic dermatitis.
20
2026
/
10
Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) recently announced that its self-developed VC005 topical gel, balanced, highly selective new-generation JAK1 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD) in adults and adolescents, has successfully completed full participant enrollment in its Phase III clinical trial. This milestone marks steady progress for the topical product toward the NDA.
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.